Ramchand Thadhani, MD
Family Medicine · Galloway, NJNPI 1619035342
Payments from drug & device makers
Across 598 payments — averaging $15.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- AstraZeneca$1K
- Johnson & Johnson$753
- AbbVie$684
- Novo Nordisk$565
- Otsuka America Pharmaceutical, Inc.$495
- plus $4K from 34 others
What the payments were for
- Food & beverage$8,986100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 109 | $1,354 |
| AstraZeneca | 39 | $1,138 |
| Johnson & Johnson | 34 | $753 |
| AbbVie(2 entities) | 65 | $684 |
| Novo Nordisk | 54 | $565 |
| Otsuka America Pharmaceutical, Inc. | 49 | $495 |
| Sanofi-aventis U.S. LLC | 8 | $464 |
| Sumitomo Pharma America, Inc. | 33 | $389 |
| Boehringer Ingelheim | 16 | $386 |
| Bayer | 18 | $349 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 44 | $308 |
| Lilly USA, LLC | 20 | $223 |
| Merck | 16 | $222 |
| Novartis | 13 | $197 |
| GSK | 6 | $180 |
| Amarin Pharma, Inc. | 4 | $149 |
| Dexcom, Inc. | 8 | $131 |
| Teva Pharmaceuticals USA, Inc. | 9 | $130 |
| Amgen | 6 | $102 |
| E.r. Squibb & Sons, L.L.C. | 3 | $93 |
| Pfizer | 6 | $84 |
| Lundbeck LLC | 4 | $69 |
| Abbott | 4 | $66 |
| Xeris Pharmaceuticals, Inc. | 4 | $60 |
| Exact Sciences | 3 | $56 |
| Sanofi Pasteur Inc. | 3 | $41 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Vanda Pharmaceuticals Inc. | 2 | $34 |
| Eisai Inc. | 2 | $28 |
| Avanir Pharmaceuticals, Inc. | 2 | $28 |
| Biogen | 2 | $27 |
| UCB, Inc. | 2 | $25 |
| Boston Scientific | 1 | $25 |
| Alkermes, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $13 |
| SK Life Science, Inc. | 1 | $13 |
| Seqirus USA Inc | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,986 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 541 | $270,735 |
| EliquisApixaban | 450 | $194,751 |
| FarxigaDapagliflozin Propanediol | 305 | $131,262 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 18 | $76,439 |
| RexultiBrexpiprazole | 61 | $60,203 |
| TrulicityDulaglutide | 30 | $54,177 |
| JanuviaSitagliptin Phosphate | 69 | $53,975 |
| XareltoRivaroxaban | 159 | $53,301 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $30,441 |
| EntrestoSacubitril/Valsartan | 76 | $28,457 |
| Atovaquone | 25 | $27,358 |
| LinzessLinaclotide | 38 | $25,409 |
| OzempicSemaglutide | 22 | $22,076 |
| MyrbetriqMirabegron | 58 | $20,858 |
| Atorvastatin Calcium | 1,015 | $18,059 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $386 | $287,891582 claims |
| PfizerEliquis | $84 | $194,751450 claims |
| AstraZenecaFarxiga, Lokelma | $1,138 | $143,243329 claims |
| Johnson & JohnsonXarelto, Procrit | $753 | $63,810183 claims |
| MerckJanuvia, Steglatro | $222 | $61,235105 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $495 | $60,20361 claims |
| Lilly USA, LLCTrulicity | $223 | $54,17730 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $180 | $51,56489 claims |
| NovartisEntresto | $197 | $28,45776 claims |
| AbbVieLinzess | $684 | $25,40938 claims |
| Novo NordiskOzempic | $565 | $22,07622 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $1,354 | $13,86722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Galloway
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.